Safety and Efficacy of EXO-CD24 in Preventing Clinical Deterioration in Patients With Mild-Moderate ARDS
NCT05947747
·
clinicaltrials.gov ↗
PHASE2
Phase
UNKNOWN
Status
90
Enrollment
OTHER
Sponsor class
Conditions
ARDS
Interventions
DRUG:
EXO-CD24
OTHER:
Placebo
Sponsor
Nano24med